Table 1.
Patient and Tumor Characteristics
| Characteristic | Total (n=497) | NLR<1.89 (n=156) | NLR≥1.89 (n=341) | p-value | PLR<149 (n=248) | PLR≥149 (n=249) | p-value |
|---|---|---|---|---|---|---|---|
| Age, yr | 64 (35–88) | 62 (35–83) | 64 (35–88) | 0.198 | 63 (35–88) | 64 (35–87) | 0.682 |
| ≤64 | 272 (54.7) | 92 (59.0) | 180 (52.8) | 138 (55.6) | 134 (53.8) | ||
| >64 | 225 (45.3) | 64 (41.0) | 161 (47.2) | 110 (44.4) | 115 (46.2) | ||
| Sex | 0.091 | 0.687 | |||||
| Female | 202 (40.6) | 72 (46.2) | 130 (38.1) | 103 (41.5) | 99 (39.8) | ||
| Male | 295 (59.4) | 84 (53.8) | 211 (61.9) | 145 (58.5) | 150 (60.2) | ||
| ECOG | 0.924* | 0.374* | |||||
| ECOG 0 | 131 (26.4) | 41 (26.3) | 90 (26.4) | 71 (28.6) | 60 (24.1) | ||
| ECOG 1 | 358 (72.0) | 113 (72.4) | 245 (71.8) | 172 (69.4) | 186 (74.7) | ||
| ECOG 2 | 8 (1.6) | 2 (1.3) | 6 (1.8) | 5 (2.0) | 3 (1.2) | ||
| Pathology | 0.157* | 0.517* | |||||
| Adenoca | 413 (83.1) | 135 (86.5) | 278 (81.5) | 209 (84.3) | 204 (81.9) | ||
| Adenosquamous carcinoma | 5 (1.0) | 0 | 5 (1.5) | 3 (1.2) | 2 (0.8) | ||
| Poor differentiated | 5 (1.0) | 0 | 5 (1.5) | 1 (0.4) | 4 (1.6) | ||
| Unknown | 74 (14.9) | 21 (13.5) | 53 (15.5) | 35 (14.1) | 39 (15.7) | ||
| Subsite | 0.014 | 0.003 | |||||
| Head | 345 (69.4) | 120 (76.9) | 225 (66.0) | 157 (63.3) | 188 (75.5) | ||
| Not head | 152 (30.6) | 36 (23.1) | 116 (34.0) | 91 (36.7) | 61 (24.5) | ||
| Clinical T stage | 0.277* | 0.013* | |||||
| T1 | 7 (1.4) | 4 (2.6) | 3 (0.9) | 3 (1.2) | 4 (1.6) | ||
| T2 | 33 (6.6) | 8 (5.1) | 25 (7.3) | 12 (4.8) | 21 (8.4) | ||
| T3 | 204 (41.0) | 69 (44.2) | 135 (39.6) | 89 (35.9) | 115 (46.2) | ||
| T4 | 253 (50.9) | 75 (48.1) | 178 (52.2) | 144 (58.1) | 109 (43.8) | ||
| Clinical N stage | 0.584 | 0.826 | |||||
| N0 | 297 (59.8) | 96 (61.5) | 201 (58.9) | 147 (59.3) | 150 (60.2) | ||
| N1 | 200 (40.2) | 60 (38.5) | 140 (41.1) | 101 (40.7) | 99 (39.8) | ||
| Tumor size, cm | 3.10 (1.20–9.00) | 3.00 (1.20–6.00) | 3.30 (1.20–9.00) | 0.006 | 3.20 (1.20–9.00) | 3.00 (1.20–9.00) | 0.346 |
| ≤3.1 | 251 (50.5) | 93 (59.6) | 158 (46.3) | 120 (48.4) | 131 (52.6) | ||
| >3.1 | 246 (49.5) | 63 (40.4) | 183 (53.7) | 128 (51.6) | 118 (47.4) | ||
| Resectability | 0.132 | 0.049 | |||||
| Unresectable | 378 (76.1) | 112 (71.8) | 266 (78.0) | 198 (79.8) | 180 (72.3) | ||
| Borderline | 119 (23.9) | 44 (28.2) | 75 (22.0) | 50 (20.2) | 69 (27.7) | ||
| Chemotherapy regimen | 0.668 | 0.501 | |||||
| Gemcitabine based | 251 (50.5) | 81 (51.9) | 170 (49.9) | 129 (52.0) | 122 (49.0) | ||
| Not gemcitabine based | 246 (49.5) | 75 (48.1) | 171 (50.1) | 119 (48.0) | 127 (51.0) | ||
| CA 19-9 | 304.5 (0–20,000) | 211.80 (0.10–20,000) | 374.00 (0–20000) | 0.031 | 305.0 (0.10–20,000) | 304.0 (0–20,000) | 0.893 |
| ≤304.5 | 247 (49.9) | 89 (57.1) | 158 (46.6) | 122 (49.6) | 125 (50.2) | ||
| >304.5 | 248 (50.1) | 67 (42.9) | 181 (53.4) | 124 (50.4) | 124 (49.8) | ||
| RT modality | 0.876 | 0.826 | |||||
| 3DCRT | 281 (56.5) | 89 (57.1) | 192 (56.3) | 139 (56.0) | 142 (57.0) | ||
| IMRT+TOMO | 216 (43.5) | 67 (42.9) | 149 (43.7) | 109 (44.0) | 107 (43.0) | ||
| TD EQD2 | 49.56 (24.42–64.31) | 49.56 (38.44–62.00) | 49.56 (24.42–64.31) | 49.56 (24.42–64.31) | 49.56 (42.47–62.00) |
Data are presented median (range) or number (%).
NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; CA, carbohydrate antigen; RT, radiotherapy; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy; TOMO, tomotherapy; TD, total dose; EQD2, equivalent dose in 2 Gy fractions.
*
Fisher exact test.